Kidney Cancer Medicine Market

Kidney cancer -- also called renal cancer -- is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Almost all kidney cancers first appear in the lining of tiny tubes (tubules) in the kidney. This type of kidney cancer is called renal cell carcinoma.
Renal cell carcinoma (RCC) is a common malignant tumor worldwide, referred to as kidney cancer. According to the World Health Organization, the global incidence of kidney cancer accounts for 2% to 3% of systemic tumors. Among malignant tumors of the urinary system, its incidence is second only to bladder cancer, and it is increasing year by year. In recent years, targeted therapy and precision therapy have become standard treatments for kidney cancer.
Kidney Cancer Medicine Market contains market size and forecasts of Kidney Cancer Medicine in Global, including the following market information:
Global Kidney Cancer Medicine Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global Kidney Cancer Medicine market was valued at 5255.3 million in 2021 and is projected to reach US$ 6545.8 million by 2028, at a CAGR of 3.2% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Monoclonal Antibody Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Kidney Cancer Medicine include Pfizer, Bristol-Myers Squibb, Roche, GSK, Novartis, Bayer, Merck & Co., Exelixis and Takeda, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Kidney Cancer Medicine companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Kidney Cancer Medicine Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global Kidney Cancer Medicine Market Segment Percentages, by Type, 2021 (%)
Monoclonal Antibody
mTOR Inhibitors
Kinase Inhibitors
Other
Global Kidney Cancer Medicine Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global Kidney Cancer Medicine Market Segment Percentages, by Application, 2021 (%)
Renal Cell Carcinoma (RCC)
Transitional Cell Carcinoma (TCC)
Global Kidney Cancer Medicine Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global Kidney Cancer Medicine Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Kidney Cancer Medicine revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies Kidney Cancer Medicine revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Pfizer
Bristol-Myers Squibb
Roche
GSK
Novartis
Bayer
Merck & Co.
Exelixis
Takeda
Eisai
CTTQ
AVEO Oncology
Everest Pharm
Cipla
NATCO
Beacon Pharma
SAMARTH